Nitrase Therapeutics
Founded 2018 · 14 employees on LinkedIn · 4 known investors
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.
Founders & leadership
Nitrase Therapeutics was founded in 2018 by Irene Griswold-Prenner.
IG
Irene Griswold-PrennerFounder & Chief Executive Officer
Investors · 4
Competitors · 5
by search overlapBioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Integrated Nanotherapeutics Inc.4 shared keywordsIntegrated Nanotherapeutics (INT) is a preclinical-stage biotech developing antigen-specific immune tolerance therapies using lipid nanoparticles to treat autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, and allergy. Its lead program, INT-101, targets Type 1 Diabetes, and the company also offers an LNP-based drug delivery platform for small molecules and nucleic acids.
Nurix Therapeutics4 shared keywordsNurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery. It uses a DEL-AI drug discovery engine to advance a multi-modal clinical pipeline targeting diseases in oncology, immunology, and neurology.
Neutrolis3 shared keywords
Doximity3 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Companies competing with Nitrase Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nitrase Therapeutics do?
- Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.
- Who founded Nitrase Therapeutics?
- Nitrase Therapeutics was founded by Irene Griswold-Prenner in 2018.
- Who are Nitrase Therapeutics's investors?
- Nitrase Therapeutics's investors include Mission Biocapital, Sofinnova Partners, Dementia Discovery Fund, Mission Bay Capital.